Ken Griffin Ventyx Biosciences, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 25,300 shares of VTYX stock, worth $47,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,300

Previous 28,200 10.28%

Holding current value

$47,311

Previous $65,000 15.38%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.85 - $3.2 $2.41 Million - $4.17 Million	-1,303,384 Reduced 22.63%	4,455,010 $9.71 Million
Q2 2024 Aug 14, 2024	SELL	$2.31 - $5.59 $306,070 - $740,663	-132,498 Reduced 2.25%	5,758,394 $13.3 Million
Q1 2024 May 15, 2024	BUY	$1.9 - $10.13 $3.09 Million - $16.5 Million	1,624,939 Added 38.09%	5,890,892 $32.4 Million
Q4 2023 Feb 14, 2024	BUY	$2.08 - $31.18 $2.76 Million - $41.4 Million	1,326,472 Added 45.13%	4,265,953 $10.5 Million
Q3 2023 Nov 14, 2023	BUY	$29.8 - $40.3 $4.54 Million - $6.14 Million	152,349 Added 5.47%	2,939,481 $102 Million
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $6.47 Million - $8.97 Million	-226,891 Reduced 7.53%	2,787,132 $91.4 Million
Q1 2023 May 15, 2023	SELL	$29.51 - $46.65 $22.2 Million - $35.1 Million	-753,320 Reduced 20.0%	3,014,023 $101 Million
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $7.16 Million - $10.8 Million	296,179 Added 8.53%	3,767,343 $124 Million
Q3 2022 Nov 14, 2022	SELL	$12.64 - $38.7 $5.31 Million - $16.3 Million	-420,164 Reduced 10.8%	3,471,164 $121 Million

Others Institutions Holding VTYX

# of Institutions

125

Shares Held

52.9M

Call Options Held

35.3K

Put Options Held

83K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $106M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account